Can a single drug hold off multiple myeloma? new trial aims to find out
NCT ID NCT05955508
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 study tests an investigational drug called linvoseltamab in 40 people with high-risk smoldering multiple myeloma, a condition that often leads to active multiple myeloma. The goal is to see if the drug can safely eliminate abnormal plasma cells and prevent the disease from progressing. The study has two parts: first checking safety in a small group, then expanding to more participants to measure effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- linvoseltamab (a drug given by injection or infusion)
- What this could lead to
- If it works, this could point toward a way to delay or prevent smoldering myeloma from turning into active multiple myeloma, potentially avoiding the need for more intensive treatments.
- What could go wrong
- This is an early Phase 2 study with only 40 people, so results may not apply to everyone. The drug can cause serious side effects like cytokine release syndrome and nerve problems, and it may not stop progression in all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMOLDERING MULTIPLE MYELOMA (SMM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinica Universidad de Navarra - Madrid
Madrid, 28027, Spain
-
Clinica Universidad de Navarra - Pamplona
Pamplona, Navarre, 31008, Spain
-
Hospital Clinic de Barcelona
Barcelona, 08036, Spain
-
Hospital Clinico Universitario Santiago de Compostela
Santiago de Compostela, A Coruna, 15706, Spain
-
Hospital Clinico Universitario Virgen De La Arrixaca
El Palmar, Murcia, 30120, Spain
-
Hospital Clinico Universitario de Salamanca
Salamanca, 37007, Spain
-
Hospital General Universitario Gregorio Maranon (HGUGM) - Instituto de Investigacion Sanitaria Gregorio Maranon
Madrid, 28009, Spain
-
Hospital Germans Trias i Pujol
Badalona, Barcelona, 08916, Spain
-
Hospital Universitari Son Llatzer
Palma Mallorca, Balearic Islands, 07198, Spain
-
Hospital Universitario Marques de Valdecilla
Santander, Cantabria, 39008, Spain
-
Hospital Universitario Quiron Salud Madrid
Pozuelo de Alarcón, Madrid, 28223, Spain
-
Hospital Universitario Ramon y Cajal
Madrid, 28034, Spain
-
Hospital Universitario Virgen de las Nieves
Granada, Andalusia, 18014, Spain
-
Institut Catala d'Oncologia
Barcelona, 08908, Spain
-
La Fe University Hospital
Valencia, 46026, Spain
-
University Hospital Doctor Peset
Valencia, 46017, Spain
-
University Hospital of Cabuenes
Gijón, Principality of Asturias, 33203, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Simple blood test could spot hidden myeloma years early
- Turmeric and black pepper extract shows promise in slowing early cancers
- Fiber-Rich diet may alter gut bacteria in early myeloma
- Simple blood test could catch myeloma years earlier in High-Risk groups
- Scientists hunt for clues to predict who will develop bone marrow cancer
- Can a drug nip myeloma in the bud? new trial aims to stop cancer before it starts